AML – Talk Bio

Actionable Insights Powered by AI

Amgen Acquires Oxford Spinout Dark Blue Therapeutics for Up to $840 Million, Gaining Preclinical Cancer Drug

3 weeks ago talkbio0Tagged Acquisition, Acute lymphocytic leukemia, amgen, AML, CSNK1E gene, Dark Blue Therapeutics, Leukemia, Myelocytic, Acute, Oxford spinout, protein degrader

Amgen; Dark Blue Therapeutics; acquisition; Oxford spinout; DBT 3757; AML; ALL; protein degrader

Kura Oncology’s Ziftomenib Achieves Phase 2 Success in AML, Paving Way for Dual-Track Phase 3 Program

12 months ago talkbio0Tagged AML, Breakthrough Therapy, DNA Sequence Rearrangement, Identifier, KMT2A gene, KOMET-001, KOMET-017, Leukemia, Myelocytic, Acute, Menin Inhibitor, Mutation, NPM1, NPM1 gene, Phase 3 trials, Ziftomenib

Ziftomenib, Acute Myeloid Leukemia (AML), NPM1 mutation, KMT2A rearrangement, Phase 3 trials, KOMET-001, KOMET-017, Menin inhibitor, Breakthrough Therapy Designation